BDBM408667 1-(7-Chloro-quinolin-3-ylmethyl)-3-methoxymethyl-1H-pyrazole-4-carboxylic acid 2-fluoro-3-methoxy-benzylamide::US10364238, Example 3::US11001578, Example 3::US11084809, Example 3::US11198691, Example 3

SMILES COCc1nn(Cc2cnc3cc(Cl)ccc3c2)cc1C(=O)NCc1cccc(OC)c1F

InChI Key InChIKey=WPIUJKAYUGBTDW-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 408667   

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 2.58E+3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 2.58E+3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 2.58E+3nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods. Human KLK1 (Callbiochem) was incubated at 25° C. with the fluoroge...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 2.58E+3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 2.58E+3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/24/2022
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 1.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods. Human KLK1 (Callbiochem) was incubated at 25° C. with the fluoroge...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/29/2020
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 1.00E+4nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods. Human plasma kallikrein (Protogen) was incubated at 2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2022
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 1.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/24/2022
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 1.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 1.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/8/2021
Entry Details
US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408667(US10364238, Example 3 | 1-(7-Chloro-quinolin-3-ylm...)
Affinity DataIC50: 4.00E+4nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2022
Entry Details
US Patent